4.7 Article

The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline

Journal

ALZHEIMERS & DEMENTIA
Volume 18, Issue 1, Pages 103-115

Publisher

WILEY
DOI: 10.1002/alz.12371

Keywords

Alzheimer' s disease; amyloid; BIN1; tau

Funding

  1. LMUexcellent Foundation
  2. Legerlotz Foundation
  3. LMU intramural funds (FoFoLe) [1032]
  4. Hertie foundation for clinical neurosciences
  5. SyNergy excellence cluster [EXC 2145, 390857198]
  6. German Research Foundation (DFG) [INST 409/193-1 FUGG]
  7. Swedish Research Council
  8. Knut and Alice Wallenberg foundation
  9. Marianne and MarcusWallenberg foundation
  10. Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
  11. Swedish Alzheimer Foundation
  12. Swedish Brain Foundation
  13. Parkinson fundation of Sweden,
  14. Parkinson Research Foundation
  15. Skane University Hospital Foundation
  16. Swedish federal government under the ALF agreement
  17. ADNI (National Institutes of Health) [U01 AG024904]
  18. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  19. National Institute on Aging
  20. National Institute of Biomedical Imaging and Bioengineering
  21. AbbVie
  22. Alzheimer's Association
  23. Alzheimer's Drug Discovery Foundation
  24. Araclon Biotech
  25. BioClinica, Inc.
  26. Biogen
  27. Bristol-Myers Squibb Company
  28. CereSpir, Inc.
  29. Cogstate
  30. Eisai Inc.
  31. Elan Phar-maceuticals, Inc.
  32. Eli Lilly and Company
  33. EuroImmun
  34. F. Hoffmann-La Roche Ltd
  35. Genentech, Inc.
  36. Fujirebio
  37. GE Healthcare
  38. IXICO Ltd
  39. Janssen Alzheimer Immunotherapy Research & Development, LLC
  40. Johnson & Johnson Pharmaceutical Research & Development LLC
  41. Lumosity
  42. Lundbeck
  43. Merck Co., Inc.
  44. Meso Scale Diagnostics, LLC
  45. NeuroRx Research
  46. Neurotrack Technologies
  47. Novartis Pharmaceuticals Corporation
  48. Pfizer Inc.
  49. Piramal Imaging
  50. Servier
  51. Takeda Pharmaceutical Company
  52. Transition Therapeutics
  53. Canadian Institutes of Health Research

Ask authors/readers for more resources

The study found that carriers of the BIN1 rs744373 risk allele showed faster global tau-PET accumulation and accelerated tau-PET accumulation at higher A beta levels. In the ADNI sample, the effects of rs744373 on cognitive decline were mediated by faster global tau-PET accumulation.
Introduction The BIN1 rs744373 single nucleotide polymorphism (SNP) is a key genetic risk locus for Alzheimer's disease (AD) associated with tau pathology. Because tau typically accumulates in response to amyloid beta (A beta), we tested whether BIN1 rs744373 accelerates A beta-related tau accumulation. Methods We included two samples (Alzheimer's Disease Neuroimaging Initiative [ADNI], n = 153; Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER], n = 63) with longitudinal F-18-Flortaucipir positron emission tomography (PET), A beta biomarkers, and longitudinal cognitive assessments. We assessed whether BIN1 rs744373 was associated with faster tau-PET accumulation at a given level of A beta and whether faster BIN1 rs744373-associated tau-PET accumulation mediated cognitive decline. Results BIN1 rs744373 risk-allele carriers showed faster global tau-PET accumulation (ADNI/BioFINDER, P P < .001). We found significant A beta by rs744373 interactions on global tau-PET change (ADNI: beta/standard error [SE] = 0.42/0.14, P = 0.002; BioFINDER: beta/SE = -0.35/0.15, P = .021), BIN1 risk-allele carriers showed accelerated tau-PET accumulation at higher A beta levels. In ADNI, rs744373 effects on cognitive decline were mediated by faster global tau-PET accumulation (beta/SE = 0.20/0.07, P = .005). Discussion BIN1-associated AD risk is potentially driven by accelerated tau accumulation in the face of A beta.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available